HighGravityDataAmgen — Feb 3, 2026 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-26-000003
Showing in the filing
Capital expenditures
“approximately $2.6 billion”
Period
FY2026
Measure
Company-defined measure
Source
Prose
All guidance in this release · 8
Net selling price for FY2026
“decline by roughly mid single-digits”
Total revenues for FY2026
“$37.0 billion to $38.4 billion”
EPS (GAAP basis) for FY2026
“$15.45 to $16.94”
Tax rate (GAAP basis) for FY2026
“15.5% to 17.0%”
EPS (non-GAAP basis) for FY2026
“$21.60 to $23.00”
Tax rate (non-GAAP basis) for FY2026
“16.0% to 17.5%”
Capital expenditures for FY2026
“approximately $2.6 billion”
Share repurchases for FY2026
“not to exceed $3 billion”
Exhibit 99.1 · the passage around this item
… earlier in the release
• On a GAAP basis, EPS in the range of $15.45 to $16.94, and a tax rate in the range of 15.5% to 17.0%. • On a non-GAAP basis, EPS in the range of $21.60 to $23.00, and a tax rate in the range of 16.0% to 17.5%. • Capital expenditures to be approximately $2.6 billion. • Share repurchases not to exceed $3 billion. Fourth Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). • MARITIME-1, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D). • MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D. AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Page 11 • MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, is enrolling adults living with established atherosclerotic cardiovascular disease and obesity or overweight. • MARITIME-HF, a Phase 3 study of MariTide on reduction of heart failure events and cardiovascular risk, is enrolling adults living with heart failure with preserved or mildly reduced ejection fraction a
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.